Market research
PBNN.F Alterity Therapeutics Limited
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 15M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 1.03
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 15M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 1.03
About
About Alterity Therapeutics Limited
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PBNN.F discussion.
5 years, 5 months ago
Alterity Therapeutics Limited is currently in a long term uptrend where the price is trading 4.9% above its 200 day moving average.
From a valuation standpoint, the stock is 46.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 704.8.
Finally, its free cash flow fell by 183.6% to $-4M since the same quarter in the previous year.
Based on the above factors, Alterity Therapeutics Limited gets an overall score of 2/5.